Back to search results
NCT05888233

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Completed
PHASE2Ages 18–75InterventionalTreatment
VA Office of Research and Development
~40 participants
Updated 2026-09-04 on ClinicalTrials.gov
What's tested:Allopurinol

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Normalized peak early diastolic filling rate (E)
Measured over 8 weeks
+8 more outcomes measured

Conditions

Heart Failure Preserved Ejection Fraction
Resistant Hypertension

Explore related trials

Heart FailureHypertension

NCT05888233

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Birmingham VA Medical Center, Birmingham, AL

    Birmingham, Alabamano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Louis J Dell'Italia, MD · PRINCIPAL_INVESTIGATOR · Birmingham VA Medical Center, Birmingham, AL

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Normalized peak early diastolic filling rate (E)8 weeks

    Change from baseline in left ventricular diastolic function index: Normalized peak early diastolic filling rate (E) after 8-weeks of treatment with Allopurinol. (Range 1.5 - 3.0 end-diastolic velocity (EDV)/second)

  • Six minute walk test8 weeks

    Change in exercise capacity by six minute walk test after 8-weeks of Allopurinol. Timed activity for distance walked (Distance range approximately 400-800 meters (m); Further distance = better outcome)

  • Self Reported health survey for Heart Failure8 weeks

    Change in self reported quality of life measures using Kansas City Heart Failure Questionnaire (KCCQ-12) after 8-weeks of Allopurinol. Scale (Minimum - 0 ; Maximum - 100; High score = worse outcome)

  • Self reported Health Survey8 weeks

    Change in self reported quality of life measures using the Quality of Life Medical Outcomes Study Questionnaire (SF 36 QOL) after 8-weeks of Allopurinol. Scale (Minimum - 0; Maximum - 100; High score = worse outcome)

  • Left ventricular end-diastolic volume index8 weeks

    Change from baseline in left ventricular diastolic function index: left ventricular end diastolic volume normalized to body surface area after 8-weeks of treatment with Allopurinol. (Range 40 - 100 milliliters per square meter (mL/m2)

  • Left ventricular (LV) end-diastolic mass index8 weeks

    Change from baseline in left ventricular diastolic function index: LV end-diastolic mass indexed to body surface area after 8-weeks of treatment with Allopurinol. (Range: 40-100 grams/square meter (m2)

  • Left ventricular (LV) end-diastolic fractional shortening8 weeks

    Change from baseline in left ventricular diastolic function index: LV end-diastolic fractional shortening after 8-weeks of treatment with Allopurinol. (Range: 15-80%)

  • Left ventricular (LV) end-diastolic mid-wall radius to wall thickness ratio8 weeks

    Change from baseline in left ventricular diastolic function index: LV end-diastolic mid-wall radius to wall thickness ratio. Ratio (no units; Range: 1.5-4.0).

  • Normalized peak late diastolic filling rate (A), EDV/s8 weeks

    Change from baseline in left ventricular diastolic function index: Normalized peak late diastolic filling rate (A) after 8-weeks of treatment with Allopurinol. (Range 1.3 - 4.5 end-diastolic velocity (EDV)/second)